New York Genome Center


The New York Genome Center is an independent 501 nonprofit academic research institution in New York, New York. It is a collaborative hub focused on genomic research that leads to new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer.

Purpose and organization

The Center leverages strengths in whole genome sequencing, genomic analysis, and development of genomic tools to advance genomic discovery. Its faculty hold joint tenure-track appointments at its member institutions and lead independent research labs at the Center.
NYGC's scientists bring a multidisciplinary and in-depth approach to the field of genomics, conducting research in single cell genomics, gene engineering, population and evolutionary genomics, technology and methods development, statistics, computational biology and bioengineering. In 2017, co-founder Tom Maniatis was named Evnin Family Scientific Director and Chief Executive Officer of the New York Genome Center.

Founding

The Center was founded in November 2011 as a collaboration among eleven academic institutions to advance genome research, based on leadership from Tom Maniatis and financial support of $2.5 million from each institution as well as from visionary private philanthropists. In November 2012, the center recruited Robert B. Darnell as President and Scientific Director, where he served as CEO and Founding Director, before returning to Rockefeller University and Howard Hughes Medical Institute Investigator in 2017 . NYGC formally opened in a multi-story building at 101 Avenue of the Americas. on September 19–20, 2013.
The 12 founding institutions were:
Currently, the NYGC has 20 member institutions with Hackensack Meridian Health and Georgetown Lombardi Comprehensive Cancer Center joining in December 2019 as associate members. and Rutgers Cancer Institute of New Jersey joining as associate member in 2020.

Funding

The New York Genome Center is a 501 nonprofit academic research institution in New York, New York. Since its inception, the Center has raised over $500 million to support its genomic research, including federal and private grants and philanthropy. This includes two joint gifts from the Simons Foundation and the Carson Family Charitable Trust; $100 million in 2016 and $125 million in 2019.
The New York Genome Center also receives support from its member institutions, as well as New York State, the Empire State Development Corporation, the Partnership Fund for New York City, and the New York City Economic Development Corporation.
Government funding has included a $55 million grant from New York State to support genomic medicine. It received a $40 million grant from the National Human Genome Research Institute to establish a Center for Common Disease Genomics, and is leading a collaborative, large-scale genomic sequencing program focused on advancing understanding of common diseases, including autism. Additionally, the Center and Weill Cornell Medicine received a National Cancer Institute grant to support a joint cancer genomics data center for the research and clinical interpretation of tumors, a part of the ongoing development of The Cancer Genome Atlas. The Center was also awarded a $13.5 million contract in 2015 to conduct whole genome sequencing and analysis for the National Heart, Lung, and Blood Institute's TOPMed program.
In 2017, New York State committed $17 million in capital improvements for the New York Genome Center to house JLABS@NYC, a life sciences incubator, which opened in summer 2018.

Notable faculty

In the last five years, NYGC scientists have published over 200 papers in leading scientific journals. For an up-to-date listing of publications, go to https://www.nygenome.org/lab-groups-overview/publications/